Breast Cancer Flashcards
Prevalence of BC
1/5 cancer deaths among women
Breast cell lining
Luminal epithelial cells lining walls of ducts
2 layers of epithelial cells :
Inner epithelial cells
Myoepithelial cells (contractile)
Differences between lobular, medullary and ductal carcinoma
Lobular: cancer with some architecture to tubes
Medullary: cells packed with neuro endocrine GFs, attract immune cells
Ductal: no distinguishing phenotype most of the time
Activation of oestrogen receptor
ERs located in cytosol Hormone binds to receptor Migration of receptor into nucleus Dimerization Binding to specific DNA sequences Cell proliferation increased = BC Many BCs are ER positive cancers that respond to oestrogen
Oestrogen regulated genes and their function
PR - makes cell more responsive to progesterone
C-myc - involved in cell survival, apoptosis
TGF-a - EGF
Cyclin D1 - regulator of cell cycle
Treatments for BC
Surgery - masectomy, lumpectomy, lymphadenectomy
RT - following surgery or if tumour too big for surgery
CT - important for ER negative cancers
Endocrine therapy - adjuvant therapy, to prevent relapse
What does endocrine therapy target?
Blocks oestrogen production
Inhibits oestrogen response
Ovarian suppression
Hormone therapy options
GnRH agonist: receptor down regulation, suppression of LH, inhibition of oestrogen production
Anti oestrogens: (Tamoxifen) competitive inhibitor, targets ER
Aromatase inhibitors: inhibit peripheral conversion of androgens to oestrogen
Tamoxifen pharmacokinetics
Selective oestrogen receptor modulator (SERM)
Competitive inhibitor of oestradiol to ER
It is metabolised to form active compound
Recruits co repressor proteins to ER which binds to DNA to modulate gene expression
Causes cell to be held at G1 leading to apoptosis
Issues with ER antagonists
Longterm administration can lead to premature osteoporosis
Tamoxifen has oestrogenic effects in bone
Side effects of ER antagonists
Thromboembolic episodes
Tamoxifen- endometrial thickening, hyperplasia, fibroids
Cataracts
Deep vein thrombosis
2 types of aromatase inhibitors
Suicide inhibitors:
Initially compete with natural substrate for binding to active site of enzyme
Enzyme acts on inhibitor which irreversibly inactivates it
Competitive inhibitors:
Bind reversibly to active site and prevent product formation as long as inhibitor occupies site
MOA of progestins
Some are AR antagonists and can be used as anti androgens
Used for uterine and breast cancer at later stage